← Back to patent-cliff list
Sucunamostat
Tier C — Watch / tradeSucunamostat
Takeda Pharmaceutical Company Limited
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Enteropeptidase
Indications (approved)：Diabetic nephropathy, Obesity, 枫糖尿病, 高苯丙氨酸血症, 高胱氨酸尿, 肾病综合征
Regional status
US
-
EU
-
China
-
Japan
No progress
2015-05-27
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sucunamostat?
Approved indications include: Diabetic nephropathy, Obesity, 枫糖尿病, 高苯丙氨酸血症, 高胱氨酸尿, 肾病综合征.
When does the Sucunamostat patent expire?
No public expiry year is available for Sucunamostat yet; this page updates once verified.
How do I get a quote for Sucunamostat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07